Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Immunic, Inc. (Nasdaq: IMUX) generates frequent news as a late-stage biotechnology company advancing oral small molecule therapies for neurologic, gastrointestinal, and other chronic inflammatory and autoimmune diseases. Most company updates center on its lead asset, vidofludimus calcium (IMU-838), and the progression of multiple sclerosis clinical programs, as well as emerging data from its gastrointestinal pipeline candidates.
News items commonly highlight clinical trial milestones, such as completion of enrollment in the twin phase 3 ENSURE trials in relapsing multiple sclerosis, new long-term open-label extension data from the phase 2 EMPhASIS trial in relapsing-remitting multiple sclerosis, and detailed results from the phase 2 CALLIPER trial in progressive multiple sclerosis. Releases also cover scientific presentations at major congresses, including oral and poster presentations at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), neuroimmunology meetings, and gastroenterology conferences.
Investors following IMUX news will also see intellectual property developments, such as Notices of Allowance from the U.S. Patent and Trademark Office for patents protecting vidofludimus calcium dose strengths and other aspects of its use in multiple sclerosis. Corporate updates regularly include financing announcements, quarterly financial results, and commentary on cash resources to support ongoing and planned studies.
For Immunic’s broader pipeline, news coverage includes analyses of IMU-856 in celiac disease and other gastrointestinal disorders, preclinical and early clinical findings related to intestinal barrier function and gut hormone levels, and the status of IMU-381 in preclinical testing. This news page aggregates these developments so readers can review clinical data readouts, conference participation, financing events, and regulatory and IP updates related to IMUX in one place.
Immunic, Inc. (Nasdaq: IMUX) recently announced the appointment of Richard Rudick, M.D. to its Board of Directors, effective
The board also confirmed the departure of Vincent Ossipow, Ph.D., effective
Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focusing on orally administered therapies for chronic inflammatory diseases, will participate in several investor and scientific conferences in May 2023. Key events include:
- Aegis Virtual Conference: CEO Daniel Vitt will present on May 4 at 11:00 am ET.
- ISIRV-AVG Conference: CSO Hella Kohlhof will discuss preclinical data on DHODH inhibitors on May 3.
- European Congress of Virology: Dr. Alexandra Herrmann will present DHODH inhibitor data on May 5.
- Digestive Disease Week: Dr. Franziska Buriánek will discuss phase 1 data of IMU-856 on May 6.
- Bio€quity Europe: CEO will present on May 15.
- XXII National Congress of Neurology: Dr. Sonya Ivanova will present EMPhASIS trial results on May 21.
For more information, visit Immunic's website.
Immunic, Inc. (NASDAQ: IMUX) announced positive results from the 50-week maintenance phase of its CALDOSE-1 trial for vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis. The 30 mg dose showed a statistically significant clinical remission rate of 61.5% versus 27.8% for the placebo (p=0.0358) and an endoscopic healing rate of 73.1% compared to 35.3% for placebo (p=0.0259). As a result, Immunic will concentrate resources on vidofludimus calcium and the IMU-856 programs while deprioritizing the izumerogant (IMU-935) program. Initial data for IMU-856 is expected this quarter.
On March 2, 2023, Immunic (Nasdaq: IMUX) announced its participation in several key investor and scientific conferences throughout March. Notable events include the BioCapital Europe conference on March 9 in Amsterdam where CEO Daniel Vitt will present at 3:20 PM CET. Additionally, the company will attend the 2023 American Academy of Dermatology Annual Meeting from March 17-21 in New Orleans, and the 32nd Annual Meeting of the Society for Virology from March 28-31 in Germany, featuring multiple poster presentations by its preclinical team.
Immunic, Inc. (NASDAQ: IMUX) reported a net loss of approximately $120.4 million for the year ending December 31, 2022, compared to a loss of $92.9 million in 2021. Their cash position stood at $116.4 million, expected to sustain operations into Q4 2024. Key developments include upcoming interim results from the Phase 2 CALLIPER trial for vidofludimus calcium in progressive MS and results from the ongoing Phase 1 trial of IMU-856 for celiac disease, both anticipated mid-2023. R&D expenses rose to $71.3 million, with significant costs related to ongoing clinical programs. An impairment of goodwill totaling $33 million was also recorded due to a stock price decline following trial announcements.
Immunic, Inc. (Nasdaq: IMUX) announced promising results from the open-label extension of its phase 2 EMPhASIS trial for vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS). Key findings show a low rate of confirmed disability worsening (CDW): only 1.6% in treatment arms versus 3.7% in placebo. After 48 weeks, 97.2% of patients were free from 12-week CDW. The data will be presented at ACTRIMS Forum 2023 in San Diego, highlighting vidofludimus calcium's potential against historical MS treatments. CEO Daniel Vitt expressed optimism about the ongoing phase 3 ENSURE program and phase 2 CALLIPER trial, set for data updates later this year.
Immunic, Inc. (Nasdaq: IMUX) has scheduled a release of its financial results for the fourth quarter and year ended December 31, 2022, on February 23, 2023, before U.S. market opening. A webcast will follow at 8:00 am ET, providing corporate updates. The company is advancing its pipeline of selective oral immunology therapies aimed at chronic inflammatory and autoimmune diseases. Key products include vidofludimus calcium (IMU-838) for multiple sclerosis, IMU-935 for psoriasis and prostate cancer, and IMU-856 focusing on bowel barrier restoration. For more details, visit Immunic's official website.
Immunic, Inc. (NASDAQ: IMUX) has announced a virtual Celiac Disease R&D Day set for February 9, 2023, from 11:00 am to 1:00 pm ET. During this webcast, management, including CEO Daniel Vitt, will discuss the complexities of celiac disease and its treatment, emphasizing the unmet medical needs of patients. Key opinion leaders Joseph A. Murray and Michael Schumann will present their insights on the immune response and intestinal barrier function in celiac disease. The event highlights Immunic's commitment to developing therapeutic options beyond the current gluten-free diet. Archived footage will be available after the event.
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, announced its participation in several key scientific and investor conferences throughout February 2023. On February 2, Darius-Jean Namdjou will join a panel on EU and UK pharmacovigilance regulations in London. A webcast on celiac disease research featuring experts will be held on February 9. CEO Daniel Vitt will present a company overview at the SVB Securities Global Biopharma Conference on February 16. Additionally, Robert J. Fox will present data on the phase 2 EMPhASIS trial at the ACTRIMS Forum in San Diego from February 23-25. More details and registration links are available on Immunic's website.
Immunic, Inc. (Nasdaq: IMUX) announced promising results from its phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) for treating relapsing-remitting multiple sclerosis (RRMS). The drug demonstrated a low rate of confirmed disability worsening (1.6%) compared to 3.7% in the placebo group over a 24-week period. Long-term treatment showed 97.6% of patients free from disability worsening after 48 weeks. The company anticipates further data from its phase 3 ENSURE program and phase 2 CALLIPER trial in 2023, highlighting the drug's potential through its neuroprotective and anti-inflammatory effects.